Shanghai, China

Jinzi Jason Wu

This inventor holds 6 USPTO granted patents and 5 published patent applications. Top assignees: Gannex Pharma Co., Ltd., Gannex Pharma Co., Ltd.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jinzi Jason Wu. Retrieved from https://idiyas.com/inventor/jinzi-jason-wu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 83.3

Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2022-2026

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Inventor Jinzi Jason Wu - Revolutionizing Technology in Shanghai

Introduction: Jinzi Jason Wu is a visionary inventor based in Shanghai, China, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Jinzi Jason Wu holds several patents in the areas of artificial intelligence, robotics, and renewable energy technologies, showcasing his commitment to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Jinzi Jason Wu has worked with leading tech companies and research institutions, spearheading projects that have revolutionized industries and improved the quality of life for many.

Collaborations: Throughout his career, Jinzi Jason Wu has collaborated with top engineers, scientists, and researchers from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Jinzi Jason Wu's relentless pursuit of innovation and his passion for creating technology that makes a difference have solidified his position as a prominent figure in the world of inventors and innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…